Peptides, FDA’s Pharmacy Compounding Advisory Committee, and the Future of FDA Drug Approval
This Viewpoint discusses the US Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee’s recommendation to add 7 peptides to the compounding 503A Bulks List and the profound threat that compounding these peptides could represent to the drug-approval process and patients.
Authors
- Peter G. Lurie (ORCID: https://orcid.org/0000-0001-7867-4951)
- Isabella Xu
- Sophia Samantaroy
Institutions
- Center for Science in the Public Interest (United States) (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-10-26
- DOI
- https://doi.org/10.1001/jama.2026.19125
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00